



Item 8.01 Other Events.

On January 29, 2014, Emergent BioSolutions Inc. announced the completion of its offering of \$250 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 and that it intends to use a majority of the net proceeds to finance the company's acquisition of Cangene Corporation. In connection with the company's issuance of the notes, the unused \$125 million term loan portion of the company's credit facility terminated automatically in accordance with the terms of the senior secured credit agreement, dated December 11, 2013, with Bank of America, N.A., as administrative agent. In addition, following the closing of the notes offering, the company repaid the \$62 million outstanding indebtedness under the revolving credit portion of the credit facility, which restored the full \$100 million revolving credit capacity under this facility. The company intends to use any remaining net proceeds from the notes offering for general corporate purposes.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 29, 2014 EMERGENT BIOSOLUTIONS INC.

/s/ Robert G. Kramer

By: Robert G. Kramer

Executive Vice President and Chief Financial Officer